Ipca Laboratories News and Updates

Name: Latest research reports of Ipca Laboratories Ltd. authored by Emkay and published by - Trendlyne research reports.
Item: Ipca Laboratories Ltd.
Rating: 5
Author: Emkay

Keep track of all breaking news on Ipca Laboratories from all sources in a single place.

Ipca Laboratories Ltd.

17 Aug 2026

2000.20

-0.40%

Ipca surges 11% in tepid market, nears 52-week high on healthy Q1 results

Business Standard

Ipca Laboratories upgraded FY27 revenue growth guidance to 14-16 per cent from 12-13 per cent and raised consolidated EBITDA margin guidance to 23 per cent from 22 per cent.

Number of FII/FPI investors increased from 246 to 256 in Jun 2026 qtr.

Ipca Laboratories Ltd.

17 Aug 2026

2000.20

-0.40%

Key investor debates beginning to settle

Buy: Ipca Laboratories Ltd.

Target

Emkay

Ipca posted a broad-based sales beat across markets (ex-branded exports) in 1QFY27, with the strong sales beat translating into a 20%/24% EBITDA beat vs our/street estimates.

Number of FII/FPI investors increased from 246 to 256 in Jun 2026 qtr.

Ipca Laboratories Ltd.

14 Aug 2026

2000.20

-0.40%

Ipca Laboratories Results Earnings Call for Q1FY27

Conference Call with Ipca Laboratories Management and Analysts on Q1FY27 Performance and Outlook. Listen to the full earnings transcript.

audio

Ipca Laboratories Ltd.

14 Aug 2026

2000.20

-0.40%

Strong execution drives a broad-based earnings beat

Buy: Ipca Laboratories Ltd.

Target

Motilal Oswal

Ipca Lab (IPCA) delivered a strong financial performance with 8%, 25%, and 34% beat on revenue, EBITDA and PAT, respectively in 1Q.

Ipca Laboratories has gained 26.13% in the last 3 Months

Ipca Laboratories Ltd.

13 Aug 2026

2000.20

-0.40%

to see Rapid results content

Ipca Laboratories Ltd.

22 Jun 2026

2000.20

-0.40%

Ipca Laboratories Creates History with GUINNESS WORLD RECORDS Title for ACNE-UV Gel by Creating Largest Card Board Box Sentence

Business Line

Mumbai, Maharashtra, India Business Wire India

Ipca Laboratories has gained 26.13% in the last 3 Months

Ipca Laboratories Ltd.

02 Jun 2026

2000.20

-0.40%

Sharp price-value disconnect emerging

Buy: Ipca Laboratories Ltd.

Emkay

Ipca’s 4QFY26 EBITDA was ahead of our expectations (broadly in line with the consensus’). The beat was driven by higher overall sales, a marginally higher gross margin, as well as lower staff costs.

Ipca Laboratories has gained 29.47% in the last 6 Months

Ipca Laboratories Ltd.

02 Jun 2026

2000.20

-0.40%

Ipca Laboratories (IPCA IN) Q4FY26 Result Update Strong FY27 guidance BUY

Buy: Ipca Laboratories Ltd.

Prabhudas Lilladhar

IPCA reported strong EBITDA of INR 4.9bn (up 19.6% YoY), 7% above our estimates. Company has guided strong revenue growth of 12-13% and 150 bps margin expansion in FY27. Our FY27 and FY28E EPS stand increased by 2-3% which factors in 11% revenue growth in FY27. Domestic formulation and branded generic business, which now contributes 46% of revenues and ~70% of EBITDA, continued to outperform and grow at healthy levels. We believe 1) recovery in API segment 2) higher margins ex Unichem 3) steady growth in domestic formulation are the key growth drivers. At CMP, the stock is trading at 14.5x EV/EBITDA and 23x PE on FY28E adjusted for Unichem stake. We...

Ipca Laboratories has gained 26.13% in the last 3 Months

Ipca Laboratories Ltd.

02 Jun 2026

2000.20

-0.40%

Ipca Laboratories

Buy: Ipca Laboratories Ltd.

Target

ICICI Direct

Q4FY26 - Formulations drive numbers- Revenues grew 6.3% YoY to 2388.5 crore, mainly driven by formulations. Domestic formulations grew 12% YoY to 853 crore. Under exports formulations - Branded exports grew ~14% to 190 crore, generic exports also grew 39% YoY to 341 crore whereas Institutional exports de-grew 33% YoY to 74.1 crore. The API business was flat at 344.6 crore. The subsidiaries (including Unichem) performance was also below par with ~6% degrowth to 574 crore. EBITDA grew 13% YoY to 483.9 crore while EBITDA margins improved...

Ipca Laboratories Ltd. has an average target of 1913.75 from 4 brokers.

Ipca Laboratories Ltd.

01 Jun 2026

2000.20

-0.40%

Domestic/exports formulation drive earnings

Buy: Ipca Laboratories Ltd.

Target

Motilal Oswal

Ipca Laboratories (IPCA) delivered in-line revenue in 4QFY28. It delivered 5% beat on EBITDA, driven by higher gross margin. PAT came in line with estimate.

Ipca Laboratories has gained 26.13% in the last 3 Months

Is Ipca Laboratories Ltd. worth buying?

375 Votes:

Buy 80.53%

Sell 9.87%

Hold 9.6%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf